Andrea Belluzzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Belluzzi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Roda
Department of Chemistry “G. Ciamician”, University of Bologna, 40126 Bologna, Italy
1 shared publication Alessandra Caponi
1 shared publicationEnrico Roda
1 shared publication- Giampaolo Ugolini
Department of Medical and Surgical Sciences, University of Bologna, Policlinico S.Orsola-Malpighi, Italy
1 shared publication Giancarlo Rosati
1 shared publication- Giulia Roda
Gastroenterology Unit, S.Orsola Malpighi , Bologna
1 shared publication
Latest Publications
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4)
M1691 IFN-γ and Lamina Propria Lymphocytes (LPLS) Regulate Sox9 and Gp180 Expression in Fresh Intestinal Epithelial Cells (IECs)
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4)
M1691 IFN-γ and Lamina Propria Lymphocytes (LPLS) Regulate Sox9 and Gp180 Expression in Fresh Intestinal Epithelial Cells (IECs)
- 1 January 2007
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 13 (10) , 1575-8
A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study
To investigate the effect of a new oral preparation, highly concentrated in fish cartilage, in a group of inflammatory bowel diseases (IBD) patients with chronic iron deficient anemia. In an open label pilot study, we supple-mented a group of 25 patients (11 with Crohn's disease and 14 with ulcerative colitis) in stable clinical conditions and chronic anemia with a food supplement which does not contain iron but contains a standardized fraction of fish cartilage glycosaminoglycans and a mixture of antioxidants (Captafer Medestea, Turin, Italy). Patients received 500 mg, twice a day during meals, for at least 4 mo. Patients were suggested to maintain their alimentary habit. At time 0 and after 2 and 4 mo, emocrome, sideremia and ferritin were examined. Paired data were analyzed with Student's t test. Three patients relapsed during the study (2 in the 3rd mo, 1 in the 4th mo), two patients were lost to follow up and two patients dropped out (1 for orticaria, 1 for gastric burning). Of the remaining 18 patients, levels of serum iron started to rapidly increase within the 2nd mo of treatment, P < 0.05), whereas serum ferritin and hemoglobin needed a longer period to significantly improve their serum levels (mo 4) P < 0.05. The product was safe, easy to administer and well tolerated by patients. These data suggest a potential new treatment for IBD patients with iron deficiency chronic anemia and warrant further larger controlled studies.
- 1 January 2007
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 13 (10) , 1575-8
A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study
To investigate the effect of a new oral preparation, highly concentrated in fish cartilage, in a group of inflammatory bowel diseases (IBD) patients with chronic iron deficient anemia. In an open label pilot study, we supple-mented a group of 25 patients (11 with Crohn's disease and 14 with ulcerative colitis) in stable clinical conditions and chronic anemia with a food supplement which does not contain iron but contains a standardized fraction of fish cartilage glycosaminoglycans and a mixture of antioxidants (Captafer Medestea, Turin, Italy). Patients received 500 mg, twice a day during meals, for at least 4 mo. Patients were suggested to maintain their alimentary habit. At time 0 and after 2 and 4 mo, emocrome, sideremia and ferritin were examined. Paired data were analyzed with Student's t test. Three patients relapsed during the study (2 in the 3rd mo, 1 in the 4th mo), two patients were lost to follow up and two patients dropped out (1 for orticaria, 1 for gastric burning). Of the remaining 18 patients, levels of serum iron started to rapidly increase within the 2nd mo of treatment, P < 0.05), whereas serum ferritin and hemoglobin needed a longer period to significantly improve their serum levels (mo 4) P < 0.05. The product was safe, easy to administer and well tolerated by patients. These data suggest a potential new treatment for IBD patients with iron deficiency chronic anemia and warrant further larger controlled studies.